I sold my remaining BIOD today at $4.73. I was really trying to avoid a repeat of my experience with DCTH earlier this year. In that instance I sold my initial 50% at +53% and the remainder at +6%. Not sure I did all that better with BIOD – the first 50% saw an improvement of 115% on the purchase price. Today’s sale of the remaining 50% yielded a 75% return. Can’t complain too much about the combined 95% return – but I wonder if there is a way that I can better protect gains.
A fairly ugly day all round. Everything I am looking at is red. ZLCS collapsing a bit in the afternoon after a flat morning while APPY has lost the decent gains it was showing in the morning.
Huge BIOD move over the last few days. Just sold half of my position at $5.84. That is 115% higher than my entry price of $2.71 on April 3rd. Will continue to hold the remainder as it approaches data.
Today opened very strongly for my two holdings building on yesterday’s momentum. Yesterday APPY closed at $1.53 – a great 11% move up from the previous day’s close at $1.38. BIOD also had a great day closing up 8% at $4.74. Based on that, my portfolio here hit a new high of $575K (indexed, as always, to the day I started tracking on this site).
APPY gapped up today and hit $1.62 soon after the opening. If gradually fell back and closed down 3.3% at $1.48.
BIOD similarly had a great first 15 minutes hitting $5.09 before eventually closing flat at $4.76. So I ended up with a down day. Holding on to both and hoping that BIOD will be able to break through the $5 barrier that it seems to have been struggling with. I am currently up 75% with BIOD and 16% with APPY.
Let’s see what can be done in H2. Have not traded anything since late April when I cut DCTH and XNPT loose. Adding APPY today at $1.28 so now have APPY and BIOD. Looking for additional positions.
I am adding two positions to the portfolio today: BIOD and RIGL. Both have trial results coming out later this year.
BIOD trades very thinly and it will take me a couple of days to get a full position in place. It has been trading in a narrow $0.35 range for the last 10 weeks or so. I am anticipating/hoping for a breakout as interest drives volume and price ahead of the phase 2 results of its ultra-fast acting insulin, BIOD-123 sometime in Q3. In today at $2.75.
RIGL is awaiting results from the OSKIRA trials of its drug, fostamatinib, in RA. AZ is conducting the trials and expects to release data in Q2. I am in this morning at $7.32.